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Phe T786C Endothelial Nitric Oxide Synthase Genotype
redicts Cardiovascular Mortality in High-Risk Patients
ian Paolo Rossi, MD,* Giuseppe Maiolino, MD,* Mario Zanchetta, MD,† Daniele Sticchi, PHD,*
uigi Pedon, MD,† Maurizio Cesari, MD,* Domenico Montemurro, MD,* Renzo De Toni, BSD,*
ilvia Zavattiero, PHD,* Achille C. Pessina, MD, PHD*
adua, Italy
OBJECTIVES This study sought to investigate the impact of a common T786C single-nucleotide
polymorphism (SNP) in the promoter of the endothelial nitric oxide synthase (eNOS, NOS3)
gene on cardiovascular (CV) death in a prospective cohort study.
BACKGROUND The T786C SNP eNOS gene implies a blunted endothelium-dependent vasodilation in
hypertensive patients and was associated with multivessel coronary artery disease in cross-
sectional studies, but it remained unsettled whether it carried prognostic information.
METHODS In consecutive white patients of the GENICA (Genetic and Environmental Factors in
Coronary Atherosclerosis) study, who underwent coronary angiography between 1999 and
2001, we determined the incidence of CV death at follow-up. The eNOS T786C and the
exon 7 G894T SNPs were determined by melting curve analysis of amplicons from
allele-specific fluorescence resonance energy transfer probes. Plasma levels of nitrate/nitrite,
nitrotyrosine, and myeloperoxidase were also measured. The Kaplan-Meier and Cox
regression analyses were used to assess the impact of SNPs on event-free survival.
RESULTS Complete follow-up data were obtained in 1,086 (98%) patients. After a median follow-up of
1,296 days (range 4 to 2,057 days), we observed 85 (8.2%) CV deaths. There was a significant
impact of the T786C eNOS genotype on CV death-free (p  0.0102) survival, but no
differences in CV death rates across G894T genotypes. The TT individuals, who showed a
lower survival, exhibited higher plasma myeloperoxidase (p  0.0001) and lower levels of
nitrotyrosine (p  0.0001) than CC patients.
CONCLUSIONS The T786C SNP in the promoter of eNOS bears independent prognostic information and
is associated with changes in markers of oxidant stress in high-risk white patients referred for
coronary angiography. (J Am Coll Cardiol 2006;48:1166–74) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.046College of Cardiology Foundation
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ehe susceptibility to coronary artery disease (CAD), the
ajor cause of cardiovascular (CV) mortality in developed
ountries, is determined by genetic factors (1); although
ome accomplishments have been made (2–4), the complex
abric of this common polygenic disorder has been difficult
o unravel (5).
See page 1175
Dysfunction of the vascular endothelium, defined as an
mpaired nitric oxide (NO) bioactivity, which is at least in
art genetically determined and can predict CV events
6–9), plays a substantial role in the triggering of athero-
enesis as well as in the erosion, or rupture, of atheroscle-
otic plaques that underlie CV events. The gene of a major
O-forming enzyme in the vasculature, the endothelial
itric oxide synthase (eNOS), entails several single-nucleotide
olymorphisms (SNPs), some of which have functional
elevance (10). The GAG to GAT substitution in exon 7
G894T) determines the conservative replacement of gluta-
From the *DMCS-Internal Medicine 4 and the †Servizio di Emodinamica and
ivisione di Cardiologia Ospedale di Cittadella, University of Padua, Padua, Italy.
his study was supported by research grants from Regione Veneto (863/01/98),
nindustria of Treviso, and F.O.R.I.C.A. to Dr. Rossi.o
Manuscript received December 23, 2005; revised manuscript received April 13,
006, accepted May 2, 2006.ate with aspartate (Glu298Asp), which might cause a
ight turn of the alpha-helix and therefore an increased
usceptibility to degradation (11). However, it remains
ontroversial whether this impairs the function of eNOS
12). According to cross-sectional studies, the T786C SNP
ocated in the eNOS gene promoter has a significant
ssociation with a blunted NO bioactivity in vivo in hyper-
ensive patients (13), and with multivessel CAD in Cauca-
ian (14,15) and Japanese patients (16). However, although
n impaired NO bioactivity has been consistently associated
ith accelerated atherosclerosis (17,18) and with CV and
erebrovascular events (6,7), cross-sectional studies can be
ampered by several biases and therefore should be taken
ith caution. Moreover, it remains altogether unknown
hether these eNOS SNPs had an impact on CV death-
nd event-free survival (19).
Thus, within the prospective branch of the GENICA
Genetic and Environmental Factors in Coronary Athero-
clerosis) study, we sought to test the hypothesis that the
894T and T786C eNOS SNPs independently predict CV
eaths.
ETHODS
tudy participants. The study protocol and criteria for
nrolment of the patients in the GENICA study were previ-
usly detailed and, therefore, will be only briefly recalled
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September 19, 2006:1166–74 eNOS Polymorphisms in Coronary Atherosclerosis14,20). Consecutive Caucasian patients referred for coronary
ngiography for investigation of chest pain and/or suspected
AD between 1999 and 2001 were enrolled upon signature
f a consent form to participate in this study. The study
rotocol was approved by the medical ethics committee.
efusal to participate was the only exclusion criterion.
nformation on medical history, smoking habits, presence/
bsence of arterial hypertension, diabetes mellitus, hyper-
holesterolemia, hypertriglyceridemia, and current medica-
ions was gathered with a staff-administered questionnaire
14). Criteria for defining body mass index, smoking
tatus, diabetes mellitus, impaired glucose tolerance,
ypercholesterolemia, and hypertriglyceridemia have al-
eady been reported (20,21). Blood pressure was mea-
ured by mercury sphygmomanometer using Korotkoff
hase V for diastolic pressure, according to the World
ealth Organization guidelines; arterial hypertension was
efined according to the European Society of Cardiology/
uropean Society of Hypertension guidelines criteria, or use
f anti-hypertensive agent(s) (22).
oronary angiography. Angiography and measurement of
eft ventricular ejection fraction (LVEF) and the grading of
he burden of CAD was carried out, as recently described
23). The severity of CAD was graded independently on an
rdinal scale on which 0% corresponded to no stenosis and
00% to vessel occlusion by two observers (M.Z. and L.P.)
ho were blinded to the patient’s genotype. The percentage
f stenosis was derived by the mean of the visual estimates
f the between-estimate difference was 20%; greater inter-
bserver disagreement in the grading of stenosis was re-
olved by consensus. The burden of CAD present was
ummarized using the Duke Prognostic Index (24), modi-
ed according to Mark et al. (25) to account for the impact
f left main trunk stenosis. This index, which accurately
redicted 5-year mortality of medically treated patients,
akes into account major epicardial coronary arteries with
50% diameter stenoses and also the location within the
essel, based on the premises that proximal coronary steno-
es have a stronger impact on prognosis than distal coronary
tenoses (26). This score goes from 0 (all major coronary
rteries with lesions50% diameter stenosis) to 100 (95%
Abbreviations and Acronyms
CV  cardiovascular
CAD  coronary artery disease
eNOS  endothelial nitric oxide synthase
HDL  high-density lipoprotein
LDL  low-density lipoprotein
LVEF  left ventricular ejection fraction
MI  myocardial infarction
MMP  matrix metalloproteinase
NO  nitric oxide
RNS  reactive nitrogen species
ROS  reactive oxygen species
SNP  single-nucleotide polymorphismeft main stenosis), and therefore provides an estimate of htherosclerotic burden, although it considers only major
picardial coronary arteries with 50% diameter stenosis.
or the purpose of comparison of haplotype frequencies,
atients were classified as non-CAD and CAD if they had
CAD score of 0 or 0, respectively.
aboratory measurements. Patients were studied between
:30 AM and 12:00 PM. Blood samples were taken immedi-
tely before coronary angiography, put on ice, and centri-
uged at 3,000  g (at 4°C for 10 min). Total cholesterol,
igh-density lipoprotein (HDL) cholesterol, triglycerides,
lycemia, sodium, potassium, and creatinine levels were
easured as described (23). All measurements as well as the
easurement of nitrate/nitrite, nitrotyrosine, and myeloper-
xidase (see later text) were performed blinded to genotype
ata.
xtraction of deoxyribonucleic acid and eNOS genotyping.
he DNA was extracted from the blood stored at 20°C
sing commercially available kits. Genotyping at the eNOS
olymorphisms was performed with LightCycler (Roche,
ilan, Italy) using melting curve analysis from an allele-
pecific fluorescence resonance energy transfer probe. This
ethod was preferred to the restriction fragment length
olymorphism analysis (which showed inconsistent cleav-
ge) because it was found to be 100% accurate when
ompared with sequencing. Primers and fluorescence reso-
ance energy transfer sequences have already been reported
n detail (14).
itrate/nitrite assay. Samples of plasma-ethylene diamine-
etraacetic acid disodium salt were filtered through a 30-
Da molecular weight cut-off filter using a commercially
vailable centrifuge ultrafiltration device (Millipore, Milan,
taly) to reduce background absorbance caused by the
resence of hemoglobin. Assay was performed with a
ommercial kit (Nitrate/Nitrite; Cayman, Ann Born, Mich-
gan) in 96-well plates using 80 l of the filtrate. The
onversion of nitrate to nitrite, which requires 3 h at room
emperature for completion, was achieved by adding 10 l
f the enzyme cofactor and 10 l of nitrate reductase to the
lasma. After incubation, 50 l of Griess reagent R1 and
mmediately after, 50 l of Griess reagent R2 were added to
ach well and the color was allowed to develop for 10 min
t room temperature. The color that developed was mea-
ured by reading the absorbance at 450 nm. The absorbance
alue of the blank wells was averaged and subtracted from
he absorbance value of all of the other wells. The nitrate
tandard curve has been used for determination of nitrite
lone. The detection limit is about 2.0 mol/l.
nzyme immunoassay for nitrotyrosine. Nitrotyrosine
as quantified by a “sandwich” enzyme-linked immu-
osorbent assay Nitrotyrosine-EIA (OxisResearch, Port-
and, Oregon). For the assay, aliquots of the plasma
amples were diluted 10 with the working dilution
uffer provided with the kit and assayed in duplicate.
ssay was performed in 96-well plates coated with a
olid-phase monoclonal antibody (nitrate keyhole limpet
emocyanin raised in mouse), and the nitrotyrosine cap-
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nti-nitrotyrosine for 2 h at room temperature, followed by
ashing the plate with phosphate-buffered saline. Sequen-
ial incubations were then performed with biotinylated goat
mmunoglobulin G and a streptavidin peroxidase conjugate
o form avidin-biotin horseradish peroxidase complex. After
urther washing, color development was initiated by the
ddition of substrate tetramethylbenzidine and was allowed
o develop in the dark for up to 30 min at room temperature
nd terminated by the addition of 2 mol/l citric acid
olution. The yellow product was measured at 450 nm. A
tandard curve was constructed by incubating in the wells
erial dilutions of 4.5 mol/l nitrotyrosine standard in
uplicate. The nitrotyrosine concentrations of the samples
ere estimated from the standard curve. The intraassay and
nterassay coefficients of variation were 2.3% and 11.2%,
espectively, and the detection limit was 2 nmol/l.
iacron reactive oxygen metabolites test septic colori-
etric assay. Samples of serum were filtered as described
bove to reduce background absorbance caused by the
resence of hemoglobin. Azo-cloro-compounds were mea-
ured with the Diacron reactive oxygen metabolites test
D-ROMs Septic Test, Diacrons, Grosseto, Italy). In the
resence of peroxides (azo-cloro-compounds), this test is
ased on the ability to catalyze the formation of free
adicals, which are trapped by an alchilamine, resulting in a
olored radical that is detectable at 505 nm. Ten microliters
f serum were mixed with 198 l of a pH 4.8 buffer and 2 l
f an alchilamine reagent, using the end point method in
he plate reader. The samples were mixed and incubated (75
in; 37°C) and read for optical density. After 10 min, the
ample was read again. The average difference in absorbance
is multiplied by the dilution factor and calculated by a
tandard curve built using serum with defined values. The
btained values were expressed as arbitrary units or CARR U,
here 1 CARR U corresponds to 0.08 mg/100 ml H2O2.
ollow-up data. Information on the long-term outcome of
he patients enrolled in the GENICA study was gathered
linded to the patient’s genotype with a predefined form,
hrough review of medical charts for the patients regularly
een at referring hospitals, and through telephone interviews
f family doctors and/or patients and first-degree relatives
or those not attending regular follow-up visits. The alive/
eath status was ascertained through on-site investigation
or all patients lost to follow-up. The predetermined pri-
ary end point was CV death, defined according to the
yst-Eur Trial (27) as sudden or as caused by congestive
eart failure, acute coronary syndromes, or stroke, and
alidated by the adjudication committee (G.P.R. and G.M.)
linded to patients’ genotypes and biochemical data. Be-
ause the exact date of occurrence of each event was
recisely known, survival data are presented in days on the
ime scale. Information on CV events, including myocardial
nfarction (MI), unstable angina, stroke, vascular surgery,
nd coronary revascularization, was also gathered. dtatistical analysis. One-way analysis of variance followed
y the Bonferroni post-hoc test was used for comparison across
enotypes. The nonparametric Mann-Whitney U test was
sed to compare plasma levels of nitrate/nitrite, nitroty-
osine, and plasma levels of myeloperoxidase between CC
nd TT patients. Chi-square analysis was used to compare
he frequencies of categorical coronary risk factors, med-
cal therapy at baseline, and the SNP across eNOS
enotypes and to verify agreement of the genotype
requency with the Hardy-Weinberg equilibrium. The
V death rates were estimated by Kaplan-Meier analysis
ith the log-rank test. Cox stepwise (backward, Wald)
nd sequential regression analysis (28) were also used to
etermine the relationships between CV death at follow-up
nd several independent variables (T786C and G894T
NOS SNPs, LVEF, gender, age, arterial hypertension,
ow-density lipoprotein [LDL] cholesterol, smoking status,
erum creatinine, diabetes mellitus, body mass index, Duke
rognostic Index, and treatment).
The modified Duke Prognostic Index was included in the
nalysis either as a continuous or as a categorical (dichoto-
ized or divided into quartiles) variable. The impact of the
786C SNP was examined according to a dominant
odel, e.g., CC  CT versus TT, because the 786C allele
as found to imply a blunted NO bioactivity in both the
eterozygous and the homozygous cases (13). Statistical
ignificance was defined as p  0.05. All analysis were
erformed using SPSS version 13 for Windows (SPSS Italy
nc., Bologna, Italy).
aplotype analysis. Linkage disequilibrium and haplo-
ype analyses were performed by use of the Thesias
rogram (29) based on the SEM algorithm (30). The
hesias program allows estimation of both haplotype
requencies and covariable-adjusted haplotype effects by
omparison with a reference haplotype taken as the most
requent haplotype in the current analyses. A global test
f association between haplotypes and any studied phe-
otype was performed by means of a chi-square test with
-1 degree of freedom in the case of m haplotypes. All
nalyses were adjusted for gender; hypotheses were tested
y means of likelihood ratio criterion. A p value 0.05
as considered significant.
ESULTS
linical characteristics and eNOS genotype distribution.
f the patients originally recruited in the GENICA study,
,104 had informative eNOS genotype data; of them 1,086
98%) had complete coronary angiography and follow-up
nformation. The coronary angiography findings in the
ENICA study high-risk cohort at the baseline evaluation
re summarized in Table 1 in the patients divided by
786C genotype. Overall, in this population of consecutive
atients referred for coronary angiography, about 25% had a
AD score of 0, and the rest had a score 0. The
emographic and clinical characteristics of these patients
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September 19, 2006:1166–74 eNOS Polymorphisms in Coronary Atherosclerosisnd the rates of treatment with different medications were
imilar across G894T eNOS (not shown) and T786C
enotypes (Tables 2 and 3). At recruitment, only 32% of the
atients were on lipid-lowering treatment, and of them half
ere within the LDL-C goal according to the National
holesterol Education Program criteria (21).
The G894T genotype distribution was GG  20.6%, GT
38.8%, and TT  40.6%; the rare (G) allele frequency is
hown in Table 4. The T786C genotype distribution was
C  19.2%, CT  41.3%, and TT  39.5%; the rare (C)
llele frequency was 0.397 (Table 4). The allele frequency of
oth SNPs are similar to those previously reported in
aucasians (31). The linkage disequilibrium was deduced
Table 1. Distribution of the Patients in the Ca
Estimated With a Modified Duke Index Progn
Extent of CAD
Progn
(
No CAD 50%
1-vessel disease 50% to 74%
1-vessel disease, 50% to 74% or 1-vessel
disease (75%)
1-vessel disease (95%)
2-vessel disease
2-vessel disease (both 95%)
1-vessel disease, 95% proximal LAD or
2-vessel disease, 95% LAD
2-vessel disease, 95% proximal LAD or
3-vessel disease
3-vessel disease, 95% in at least one
3-vessel disease, 75% proximal LAD
3-vessel disease, 95% proximal LAD
Left main (75%)
Left main (95%)
Chi-square  14,320, p  NS.
CAD  coronary artery disease; LAD  left anterior de
Table 2. Demographic and Clinical Characteri
Genotype
Variable (n  4
Age (yrs) 63.
Gender (male/female) 330 (76%
Nonsmoker/smoker/ex-smoker (%) 42
BMI (kg/m2) 26.
Serum creatinine (mol/l) 98.
Serum K (mmol/l) 4.
Serum Na (mmol/l) 14
Heart rate (beats/min) 6
Systolic BP (mm Hg) 13
Diastolic BP (mm Hg) 7
Glycemia (mmol/l) 6.
Total cholesterol (mg/dl) 20
HDL cholesterol (mg/dl) 4
LDL cholesterol (mg/dl) 13
Triglycerides (mg/dl) 13
Left ventricular EF (%) 6
Results are expressed as mean  SD. No significant differen
BMI  body mass index; BP  blood pressure; EF  ejection
high-density lipoprotein; LDL  low-density lipoprotein.rom the estimated haplotype frequencies, and its extent was
xpressed in term of D= that is the ratio of the unstandard-
zed coefficient to its maximal/minimal value (Table 4) (32).
he distribution of both genotypes agreed with the Hardy-
einberg equilibrium. No differences of genotype frequencies
etween the non-CAD and CAD groups were observed.
aplotype analysis. The two genotypes for the eNOS
ene resulted in four possible haplotypes, the frequencies of
hich are given in Table 5. The haplotype distribution did
ot differ between non-CAD and CAD groups. However, a
ignificant association between haplotype T894/C786 and the
AD index score was found (p  0.031) after adjustment for
ffects of age, creatinine, LVEF, and arterial hypertension. A
ries of CAD Atherosclerotic Burden
Score
Weight
0)
Patients Stratified by
T786C Genotype
TT
(n  436, 39.5%)
TC and CC
(n  668, 60.5%)
20.9 27.1
6.5 6.4
16.4 16.8
9.3 9.1
15.5 14.0
1.6 2.9
10.0 7.0
3.9 4.2
5.3 4.2
3.7 3.8
2.8 1.7
3.9 2.3
0.2 0.5
ng coronary artery.
of the Patients Stratified by T786C eNOS
9.5%)
TC and CC
(n  668, 60.5%) p
0.1 63.6  9.5 NS
6 (24%) 487 (73%)/181 (27%) NS
3 43/14/43 NS
.1 26.9  3.9 NS
7.9 93.7  54.0 NS
.4 4.2  0.4 NS
140  3 NS
0 67  10 NS
7 135  18 NS
0 79  10 NS
.0 6.2  1.9 NS
3 205  43 NS
2 46  13 NS
6 130  35 NS
4 143  100 NS
5 60  15 NS
ross genotypes were found.tego
ostic
ostic
0–10
0
19
23
32
37
42
48
56
63
67
74
82
100stics
TT
36, 3
9  1
)/10
/15/4
9  4
6  6
3  0
0  3
8  1
4  1
8  1
2  2
6  4
6  1
2  3
8  7
0  1
ces ac
fraction; eNOS  endothelial nitric oxide synthase; HDL 
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eNOS Polymorphisms in Coronary Atherosclerosis September 19, 2006:1166–74orderline significant association of the T894/T 786haplotype
ith CV death was also found (p  0.066).
iochemical markers. For these assays based on sample
ize calculations (nQuery Advisor version 6.0 L, Statistical
olutions, Cork, Ireland), we randomly selected 88 CC and
8 TT homozygous patients. Of these, 113 were on nitrate
reatment and 63 were not. The plasma nitrate/nitrite values
ere similar to those previously described (33,34); however,
here were no differences observed between CC and TT
ndividuals and between patients receiving and not receiving
itrates. At variance, highly significant differences of plasma
itrotyrosine and myeloperoxidase levels between CC and TT
atients were observed (Fig. 1): nitrotyrosine, which showed
alues similar to those seen in diabetic patients (35), was higher
n CC individuals. By contrast, myeloperoxidase was lower in
C than in TT patients. All of these differences were more
arked in the patients without concomitant nitrate treatment.
ollow-up data. After a median follow-up of 1,296 days
range 4 to 2,057 days), 85 CV deaths occurred. There were
o significant differences in CV death rates across G894T
enotypes by chi-square, Kaplan-Meier, and Cox regression
nalyses (not shown). By contrast, there were more CV
eaths in the 430 TT homozygous for the T786C eNOS
NP than in the 656 CC CT individuals (43 [10%] vs. 42
7%], respectively, chi square  4.47, p  0.03). Kaplan-
able 4. Allele Frequencies and Pairwise Linkage
isequilibrium D= Between C894T and T786C Polymorphisms
Genotype Rare Allele Frequencies G894T
894T 0.394 —
786C 0.397 0.30*
p value  0.0001. Values were similar in the non-CAD and CAD. Pairwise linkage
isequilibrium was deduced from the estimated haplotype frequencies, and its extent
as expressed in term of D=, that is, the ratio of the unstandardized coefficient to its
able 3. History and Medical Treatment in the Patients
tratified by T786C eNOS Genotype
History and Treatment (%)
TT
(n  436)
TC and CC
(n  668) p
revious CABG 9 8 NS
revious PTCA 5 7 NS
revious MI 32 33 NS
ntiplatelet agents 69 69 NS
alcium channel blockers 35 39 NS
eta-blockers 36 38 NS
ngiotensin-converting enzyme
inhibitors
49 45 NS
itrates 59 63 NS
arfarin 6 6 NS
lpha-1 receptor blockers 4 4 NS
ngiotensin type I receptor blockers 6 4 NS
iuretics 34 34 NS
eparin 19 21 NS
igoxin 13 13 NS
ipid-lowering treatment 29 34 NS
esults are expressed as percentage. No significant differences across genotypes were
ound.
CABG  coronary artery bypass graft; MI  myocardial infarction; PTCA 
ercutaneous coronary angioplasty.aximal/minimal value.
CAD  coronary artery disease.
t
feier analysis confirmed the impact of the T786C eNOS
enotype on CV death-free survival by evidencing a signif-
cantly (p  0.01) worse CV death-free survival in the TT
han in the CT and CC individuals (Fig. 2). At Cox
egression analysis, when the potential confounders of the
enotype effect on outcome were considered, the significant
mpact of the TT eNOS genotype on CV death-free
urvival was consistently confirmed by using different re-
ression models within the constraints imposed by the
umber of CV deaths observed. Table 6 showed the
ariables that remained in one such model. Of interest, the
ultivariate Cox regression analysis showed that the prog-
able 5. Estimated Haplotype Frequencies Under Linkage
isequilibrium in Non-CAD and CAD Patients
Haplotype
Non-CAD
(CAD Index Score  0)
CAD
(CAD Index Score >0)
894/C786 0.196 0.163
894/T786 0.408 0.444
894/C786 0.242 0.221
894/T786 0.153 0.173
o significant differences of haplotype frequencies between non-CAD and CAD
atients were found. Statistical values were adjusted by gender.
CAD  coronary artery disease.
igure 1. The histograms showed the plasma levels of nitrate/nitrite
upper panel), nitrotyrosine (middle panel), and myeloperoxidase (bottom
anel) in randomly selected CC (n  88) and TT (n  88) patients. The
anels on the left showed all of the cohort; those on the right pertain to
he CC (n  26) and TT (n  37) patients who were not receiving nitrate
or treatment of coronary artery disease (CAD).
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September 19, 2006:1166–74 eNOS Polymorphisms in Coronary Atherosclerosisostic impact of the TT homozygosity exceeded that of
ome well-established CV risk factors that did not remain in
he model. To corroborate the results obtained with the Cox
tepwise regression, we used the sequential regression tech-
ique described by Tabachnick and Fidell (28), which
llows the researcher to control the advancement of the
egression process, rather than have the statistics computed
rom data control entry of variables. Results obtained with
oth regression techniques were practically identical. They
ere also remarkably similar when the Cox analysis was
epeated after exclusion of the patients who were on
ipid-lowering treatment, thus ruling out the possibility that
he small and not significant differences in the treatment
ate across genotypes at baseline might have affected the
NOS genotype impact on CV death-free survival. More-
ver, by performing the Kaplan-Meier and Cox analyses
eparately in the normotensive and hypertensive cohort, the
mpact of the T786C eNOS genotype on CV death-free
urvival was found to be particularly evident in the patients
ith arterial hypertension.
The adverse significant impact of the TT eNOS genotype
as confirmed at Kaplan-Meier analysis also on the secondary
V end point, e.g., a composite of the aforementioned CV
vents (not shown). At variance with these results, no signifi-
ant association of the most common haplotypes (shown in
able 5) with the primary or secondary end points was found.
ISCUSSION
he identification of the genetic determinants of the sus-
eptibility to common polygenic disorders, such as CAD
nd CV events, requires a careful investigative strategy, a
igorous methodological approach, a selection of biologi-
ally plausible candidate genes and, within them, of func-
ional SNPs. Equally important, solid data can only derive
igure 2. Results of Kaplan-Meier analysis showing cardiovascular (CV)
eath-free survival in the high-risk patients divided by the T786C
ndothelial nitric oxide synthase (eNOS) genotype. The TT homozygous
atients had a significantly lower CV death-free survival.rom studies adequately powered from the statistical stand-
Doint, such as the prospective survey of high-risk cohorts of
atients, in whom a high rate of CV events occurs in a
imited period of time.
A preliminary survey of the cross-sectional data of the
ohort enrolled in the GENICA study indicated that 97%
f the patients were at high CV risk according to the ATP
II (National Cholesterol Education Program [Adult Treat-
ent Panel III]) criteria (21), and had a constellation of risk
actors and associated conditions that imply oxidant stress
nd blunted NO bioactivity. Hence, despite an LVEF that
n average was normal, a very high rate of CV deaths was
bserved at follow-up in these CAD patients. Thus, this
tudy was adequately powered to address the hypothesis that
he eNOS variant impacted survival. Formal calculation of
ower by nQuery (version 6.0) confirmed this prediction by
howing that given our sample size, a total number of 79
vents, e.g., smaller than that actually observed, provided a
5% power to detect a 6% difference of survival curves
etween a CC  CT and TT genotype groups at a 0.05-
evel two-sided log-rank test, assuming no drop-outs.
894T exon 7 eNOS SNP and survival. We found no
vidence for an effect of the G894T SNP on total and CV
eath with different analyses. This negative finding con-
rasts with results of two studies that reported a correlation
ith MI (36,37), but accords well with the conclusions of a
rospective study of high-risk Japanese nondiabetic hemo-
ialysis patients (38), and also with previous evidence for no
ssociation of this SNP with the severity of CAD
14,16,31,39–41). It also accords with the fact that the
lu298Asp is a conservative replacement that may have no
unctional effect (12). Moreover, studies in vivo in humans
uggested that it might affect NO bioactivity only through
n interaction with the T786C SNP (13), likely because the
SNPs are in linkage disequilibrium as shown in Table 4.
786C promoter eNOS SNP and survival. Our results
howed that the T786C SNP in the eNOS gene promoter
ad a significant impact on CV death-free survival: the
urvival curve of the TT patients started to diverge after a
ag-phase of about 500 days and continued to do so
fterward (Fig. 2). Of interest, the haplotype analysis also
uggested a worse CV death-free survival in patients with
he T786 allele, e.g., with the T894/T786haplotype. Re-
orter gene studies showed that this T786C substitution
able 6. Cardiovascular Death-Free Survival at Cox Regression
nalysis
Variables p
Odds
Ratio
95%
Confidence
Interval
eft ventricular ejection fraction 0.0001 0.95 0.93–0.96
ge 0.002 1.05 1.02–1.09
786C genotype (CC  CT vs. TT) 0.006 2.14 1.24–3.67
he variables that remained in the model are reported along with significance values
nd 95% confidence interval. The following variables did not remain in the model: the
894T eNOS SNP, gender, arterial hypertension, LDL cholesterol, smoking status,
erum creatinine, diabetes mellitus, coronary artery atherosclerotic burden and (CAD
uke Index).
Abbreviations as in Table 2.
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42), and hence NO production, likely because the C allele
reates a binding site for a replication protein A1 that acts
s a suppressor of eNOS transcription (43). We previously
bserved a blunted NO bioactivity in vivo in hypertensive
atients with the C allele (13), and these results were
hereafter confirmed by the demonstration that the C allele
mplies a blunted eNOS transcription in response to shear
tress (15), which is a crucial determinant of basal NO
roduction (44). Notwithstanding these functional data, we
ould find no evidence for an effect of this SNP on
itrate/nitrite plasma levels (Fig. 1) in keeping with previ-
us albeit not all findings (31,33). The fact that this
easurement is affected by dietary factors and by contribu-
ions of other NOS enzymes can well account for these
esults (31). Thus, although available findings overall are
onsistent with a relevant biological role of the T786C, our
ndings show for the first time an effect of this SNP on
urvival in high-risk individuals.
otential explanations for the impact of the T786 allele
n survival. The association of gene variants with complex
henotypes such as CAD and CV events, which involve
umerous mechanisms and therefore have multiple deter-
inants, can be affected by several confounders. These
eserve careful consideration when analyzing of the results
ecause overlooking them can lead to misleading conclu-
ions. As an example, the coronary atherosclerotic burden
iffers among patients carrying the different T786C geno-
ypes (14–16). Furthermore, in this type of study, the
istribution of major risk factors, associated CV conditions,
nd pharmacological treatment is usually unbalanced be-
ween the patients experiencing and those not experiencing
V events. Therefore, we used a hierarchical sequential type
f Cox regression analysis (28) in which the major deter-
inants of outcome, e.g., LVEF, coronary atherosclerotic
urden (24,25), gender, age, arterial hypertension, hyper-
holesterolemia, smoking status, serum creatinine, diabetes
ellitus, and rate of lipid lowering treatment, were consid-
red. This technique, which allows control over the ad-
ancement of the regression process (28), fully confirmed
he results obtained with a classic stepwise regression
nalysis. Thus, results obtained with either technique sup-
ort an independent significant impact of the eNOS pro-
oter SNP on CV death. This is important novel informa-
ion that, in our view, is even more striking given the
igh-risk features of this cohort. Moreover, the impact of
he T786C genotype on CV death remained significant
hen the modified Duke Prognostic Index was handled
ither as categorical or as a continuous variable and also
hen the rate of lipid-lowering treatment was considered in
he Cox analysis.
The worse CV death-free survival of the TT homozygous
s compared to the other eNOS genotypes (Fig. 2) is
ntriguing given the aforementioned association of the
allele with blunted NO bioactivity (13), and with mul-
ivessel CAD (14,16). Notably, a significant association of ahe C allele with CAD was also confirmed by our present
nalysis, in which the T894/C786 haplotype correlated
ignificantly with the CAD index score. Moreover, an
ssociation of the 786C allele with CV events in Japanese
emodialysis patients has also been recently described (37).
he race differences between the latter patients and our
ohort are obvious; furthermore, patients with end-stage
enal disease are likely to have an accumulation of the
ndogenous NO inhibitor asymmetric dimethylarginine
45). Hence, a deleterious impact of the genetic predispo-
ition to generate more NO is unlikely in these patients.
oreover, our present finding that the T786 allele, which
an imply a higher NO bioactivity, is associated with
ncreased CV death, along with the recently reported
ssociation of the same allele with previous MI in Cauca-
ians (46), seems to be paradoxical. Nonetheless, along with
he conflicting results in this area of research (47), it raises
ome provocative questions on the potential clinical impor-
ance of the genetic predisposition to generate NO in the
ong run.
It must also be acknowledged that the determinants of
laque growth, e.g., of the atherosclerotic burden, and of
laque destabilization, e.g., of CV events, differ even though
hey can overlap. Fatal MI and atherothrombotic stroke are
ommonly triggered by rupture of vulnerable atherosclerotic
laques, with the propensity of rupture enhanced by several
actors involving matrix metalloproteinase (MMP) activa-
ion. Of note, peroxynitrite (ONOO), originating from
O and superoxide anion (48), can activate MMPs in
laques, thus contributing to plaque destabilization (49,50).
urthermore, it was recently shown that oxidized LDL
ause eNOS uncoupling and increase superoxide anion
roduction in endothelial cells in vitro by inhibiting protein
inase C-alpha and thereby blunting the phosphorylation of
NOS Thr495 (51).
The GENICA study enrolled high-CV-risk patients in
hom enhanced oxidant stress is the rule rather than the
xception: they were chronically exposed to oxidatively
odified lipoproteins (20), and therefore might have un-
oupling of eNOS. Accordingly, the predisposition to
enerate more NO of the homozygous TT can result into a
igher generation of ROS and reactive nitrogen species
RNS), including ONOO, with ensuing MMP activation.
n addition, it has been shown that chronic exposure to
NOO irreversibly oxidizes relevant cysteine thiols in
arcoplasmic/endoplasmic reticulum Ca2 adenosine
riphosphatase, thus blocking Ca2 uptake and thereby
mpairing NO-dependent arterial relaxation (52). Accord-
ngly, under conditions with enhanced ROS/RNS genera-
ion, a genetic predisposition to generate more NO might
e detrimental in the long run. In fact, it might result in
mpairment of both sarcoplasmic/endoplasmic reticulum
a2 adenosine triphosphatase activity and arterial dilata-
ion, and activation of MMPs, with ensuing plaque rupture,
therothrombosis, and fatal CV events.
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September 19, 2006:1166–74 eNOS Polymorphisms in Coronary AtherosclerosisTo gain some mechanistic insight, we measured two
arkers of oxidant stress in plasma, e.g., nitrotyrosine and
yeloperoxidase. The former is held to derive from
NOO effect on protein tyrosine residues, and the latter
eflects oxidant burst in polymorphonuclear neutrophils
nd was found to be associated with CAD (53,54). Our
esults showed that nitrotyrosine levels were markedly
igher in the CC compared with the TT individuals (Fig.
), in contrast with our expectations. Although indicating
hat the plasma levels of this marker do not accurately
eflect NO bioactivity of CC individuals (13), these
esults may suggest NO consumption in the TT patients.
otably, the fact that these patients concomitantly had
arkedly higher myeloperoxidase values than CC pa-
ients (Fig. 1), along with the fact that myeloperoxidase
onsumes NO (54), might account for the lower nitro-
yrosine levels. It can explain, at least in part, the worse
V death-free survival in this genotype, because myelo-
eroxidase activates MMPs and was found to predict risk
f CV events in patients with acute coronary syndromes
54). Thus, our results overall suggest a link between the
786C eNOS genotype and leucocyte activation, leading
o increased ROS/RNS generation locally with atheroscle-
otic plaque. Further investigation is obviously necessary to
larify its nature.
Finally, although the possibility of a serendipitous finding
an never be totally excluded in clinical research, we would
ike to underline that prospective cohort studies, such as the
resent one, have a stronger design and therefore usually
rovide more robust conclusions than cross-sectional stud-
es, which are exposed to several potential biases that might
ffect results and conclusions (55).
onclusions. Our results shown that in a high-risk popu-
ation of consecutive patients referred for coronary angiog-
aphy, a functional polymorphism of the promoter region of
he eNOS gene predicted CV death independent of other
ommon CV risk factors and of the CAD atherosclerotic
urden. They also documented clear-cut differences of
lasma nitrotyrosine and myeloperoxidase levels between
C and TT homozygous patients. These findings collec-
ively raise provocative questions regarding the importance
f the genetic predisposition to generate NO in these
atients that should prompt further research on the molec-
lar mechanisms that are involved in atherosclerotic plaque
rosion and rupture and imply NO bioactivity and oxidant
tress.
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